Connection

Michael Hallek to Imatinib Mesylate

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Imatinib Mesylate.
Michael Hallek
Connection Strength
0.135
Imatinib Mesylate
  1. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer. 2017 Feb 28; 116(5):600-608.
    View in: PubMed
    Score: 0.135
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.